Business Wire

NSK

27.2.2015 09:07:59 CET | Business Wire | Pressemeddelelse

Del
NSK Put Smart Spin on Moving Parts Big and Small in 2014

Unless you are a mechanical engineer, you probably don’t wake up in the morning thinking about bearings. More likely, you never even notice that bearings – working away unseen – are the critical components in everything mechanical that moves: from jumbo-jets to nano-tools, kitchen blenders to concrete mixers. To meet the vast scope of “Motion and Control” needs, NSK (TOKYO:6471) – the world’s No. 3 bearing manufacturer – must offer over 200,000 different bearings, from microscopic to mammoth. And each year customers bring new challenges to NSK researchers: needs for new bearings to meet specific performance constraints. Here are two challenges that NSK researchers successfully overcame in 2014.

Wind turbines: reliable rotation under the harshest conditions

Since the dawn of the new millennium wind energy has grown full-sail from fringe power source to grid mainstay in countries around the world. NSK has been a key player in the expansion of global installed generation capacity from 17.4 gigawatts in 2000 to more than 305 gigawatts by the end of 2014 – but its role may not be obvious to the casual observer.

Anyone seeing images of a giant offshore wind turbine might naturally assume its giant blades are the critical technology involved. But the real key to the success of these gargantuan machines is in the bearings, which must function reliably for years under extremely adverse conditions: massive and rapidly shifting loads; dramatic fluctuations in temperature; and salty ocean air. Their location atop high towers in windy seas makes even inspecting an offshore turbine an arduous task. So swapping out heavy components is a huge undertaking. That is why bearing durability and reliability is the critical factor in the economic viability of wind power.

With the benefit of two decades’ experience in the challenge, NSK engineers achieved increased durability and reliability for white structure flaking in the roller bearings used in the gearboxes of large wind turbines, as well as in giant mining, construction and steelmaking equipment.

NSK’s solution was a specially developed material combined with a proprietary heat treatment process that dramatically increases the service life of the bearings. Incorporated in a new large-size roller bearing (AWS-TFTM ) launched in May, 2014, the innovative technology offers longer service life than previous products by, several critical measures:

  • 7 times longer without “white structure flaking”
  • 3 times longer without “surface originated flaking”
  • Twice as long without “subsurface originated flaking”
  • Twice the fracture toughness
  • 1/50 the dimensional change rate

This advance is expected to contribute significantly to the long-term economic viability of wind turbines. NSK expects sales of the new bearings to reach 1 billion yen (roughly $8.5m) in annual global sales by 2017.

For more information, see: www.nsk.com/company/presslounge/news/2014/press0527a.html

Heavy-duty spin for more laundry without more space

While wind turbines are exponentially larger and more sophisticated than your household washing machine, they share a similar need for a reliable spin cycle over many years. Here again bearings are the key component.

For European appliance makers, the home laundry spec has become more challenging in recent years. Today’s front-loading washer buyers want more laundry capacity, but in the same space occupied by their previous machines. That is a challenge because what makers would normally do with a larger, heavier laundry drum is simply fit larger, heavier-duty bearings. This led to a conundrum: larger bearings would mean lower energy efficiency, but fitting the previous bearings on a larger drum would result in shorter product life. So the manufacturer came to NSK for help.

As with giant wind turbines, the obstacle to overcome was a tendency of the non-metallic inclusion in the bearings to flake or crack after years of vibration. The larger the load, the greater the tendency. As well, there was a harsh environment to consider: heat, moisture, soap, dirt and mold to contend with.

NSK’s solution, released in December, 2014, is the BNEQARTET™ Long Life Bearing for Front-Loading Washers. Even under heavier loads, it achieves more than twice the product life of the standard bearing used for drum support in front-loading washers, but takes up no more space.

NSK leveraged one of its core material technologies in developing the material for this new bearing, through a combination of alloy component optimization and proprietary cleaning control technology to counter the possibility of contamination. The result:

  • Twice the rated fatigue life
  • Suppression of surface-originated flaking due to stress concentration from dents caused by contamination
  • Suppression of “white structure flaking”
  • Suppression of flaking in high-temperature environments

NSK is targeting 1.5 billion yen (roughly $12.5m) in annual global sales for this new product in 2018.

For more information, see: www.nsk.com/company/presslounge/news/2015/press0114b.html

Here’s the final ‘spin’ on these two stories. As a result of NSK’s efforts, many washing machines will soon make more efficient use of energy – sustainably produced by the wind.

About NSK

In 2016, NSK Ltd. (NSK; Headquarters: Tokyo, Japan; President and CEO: Norio Otsuka) will celebrate a century of innovation since its founding as Japan's first bearings manufacturer. With the theme “Motion & Control” at the core of its business, NSK today is a global enterprise with 213 facilities in 31 countries that serve a diverse range of industrial customers with a wide range of precision components in addition to bearings. The company provides customers with total solutions through its world-leading technologies, sales force and customer service capabilities.

Contact:

NSK
Makiko Urushino
urushino@nsk.com
Fax: 81-3-3779-7431

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye